Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
While the company has shown improvements in operating expenses and net loss, revenue guidance has been lowered. The Q&A revealed positive sentiment towards the next-gen Tablo's potential impact but lacked specifics on ASP lift and gross margin timelines, which may cause uncertainty. The mixed signals from strong financial metrics but weak guidance, coupled with optimistic future prospects, suggest a neutral short-term stock price movement.
Key Financial Performance
Revenue for Q4 2025 $28.9 million, consisting of $19.9 million in product revenue and $9 million in service and other revenue. Product revenue was below $21 million in Q4 2024 due to order timing. Console sales grew 11% to $6.4 million, while consumable sales were $13.5 million. Service and other revenue grew 6% from $8.5 million in Q4 2024.
Gross Margin for Q4 2025 42.9% non-GAAP, expanded more than 500 basis points year-over-year. Product gross margin increased 640 basis points to 50.7%, marking the first time it exceeded 50%. Service and other gross margin grew 470 basis points to 25.6%.
Operating Expenses for Q4 2025 Non-GAAP operating expenses declined nearly 4% to $25.7 million, compared to $26.6 million in Q4 2024.
Operating Loss for Q4 2025 Non-GAAP operating loss was $13.3 million, 14% lower than $15.5 million in Q4 2024.
Net Loss for Q4 2025 Non-GAAP net loss was $15 million, 22% lower than $19.3 million in Q4 2024.
Cash Usage for Q4 2025 Approximately $9 million in cash was used during the quarter.
Full Year 2025 Revenue $119.5 million, a 5% increase over 2024. Product revenue was $84.8 million (5% increase), service and other revenue was $34.7 million (6% increase), and recurring revenue was $88.7 million (6% increase).
Full Year 2025 Gross Margin 39.6% non-GAAP, increased 400 basis points year-over-year. Excluding manufacturing under-absorption, gross margin was 41.1%.
Full Year 2025 Operating Expenses Non-GAAP operating expenses were $97.8 million, a 19% reduction from $120.7 million in 2024.
Full Year 2025 Net Loss Non-GAAP net loss was $65.4 million, a 31% decline compared to $94.8 million in 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA clearance of next-generation Tablo platform: Received FDA clearance for the next-generation Tablo platform, which includes hardware and software enhancements, improved performance, system reliability, and compliance with 2025 cybersecurity requirements.
Innovation and future enhancements: The next-generation Tablo serves as a foundation for future innovations, with planned enhancements to strengthen its position in the acute and home market.
Expansion in acute care sites: Tablo is now used at approximately 1,000 acute care sites in the U.S., including agreements with one of the largest national health systems with over 100 facilities.
In-sourcing dialysis benefits: Gained momentum from nursing leaders highlighting improved clinical outcomes, such as lower infection rates, reduced length of stay, and higher nurse satisfaction.
Gross margin improvement: Achieved a non-GAAP gross margin of 39.6% for 2025, with gross margin exiting the year above 40%, and product gross margin exceeding 50% for the first time.
Cost structure and cash usage: Reduced cash usage by $70 million and operating expenses by 19% year-over-year, narrowing the operating loss and driving towards profitability.
Cybersecurity as a competitive advantage: The next-generation Tablo platform meets stringent FDA cybersecurity requirements, addressing critical patient safety concerns and providing a competitive edge.
Recapitalization and leadership strengthening: Recapitalized the company with less debt and new capital, and infused new talent into key leadership roles in finance, medical affairs, and field service.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cybersecurity Risks: The transcript highlights the increasing threat of cyberattacks in the healthcare sector, with 93% of healthcare organizations experiencing at least one cyberattack in the past year. These attacks can disrupt patient care, reduce hospital capacity, and strain staffing, posing a significant risk to operations and patient safety.
Revenue Volatility: The company experienced fluctuations in consumable sales due to order timing, which impacted revenue predictability. This indicates a challenge in maintaining consistent revenue streams.
Manufacturing Under-Absorption: The company faced a 130 basis-point headwind from under-absorption of manufacturing overhead, which negatively impacted gross margins. This issue is expected to diminish in 2026 but remains a current challenge.
Cash Usage: Despite reducing cash usage by $70 million in 2025, the company still used $46 million in cash, with expectations of high cash use in Q1 2026 due to planned investments. This indicates ongoing financial pressure.
Regulatory Compliance: The company must comply with stringent FDA cybersecurity requirements for its next-generation Tablo platform. While this is a competitive advantage, it also represents a regulatory challenge.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations for 2026: Revenue is expected to be in the range of $125 million to $130 million, representing a 5% to 9% increase over 2025. The first quarter is expected to be roughly flat compared to Q4 2025, with growth stepping up through the rest of the year.
Gross Margin Projections: Non-GAAP gross margin is expected to be in the low to mid-40% range. A higher console mix could lower gross margin, while a higher mix of consumables could increase it. The manufacturing under-absorption headwind from 2025 is expected to diminish in 2026.
Operating Expense Growth: Operating expense growth is anticipated to be roughly half the rate of expected sales growth, reflecting continued operating leverage.
Cash Usage in 2026: Cash use is expected to be lower than the $46 million used in 2025. Q1 2026 is projected to be the highest cash use quarter due to planned investments in inventory and manufacturing.
Next-Generation Tablo Platform Launch: The next-generation Tablo platform, which includes hardware and software enhancements and meets FDA's 2025 cybersecurity requirements, is planned for launch toward the end of Q2 2026. Future enhancements are also planned to further innovate and strengthen the platform.
Market and Growth Expectations: The company expects to drive growth for many years with the next-generation Tablo platform and a rich roadmap of additional innovations. The strong pipeline reflects benefits from in-sourcing dialysis with Outset's technology and service.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you tell us a little bit about how the next-gen Tablo might change the markets you can go after, the types of hospitals you can target, and whether it might change your sales cycle timelines? Also, will there be any ASP lift from the launch?
A:The next-gen Tablo, being the first dialysis system harmonized with FDA's rigorous cybersecurity standards, is expected to generate incremental attention and interest among hospitals of all sizes. Cybersecurity is a major concern for health system executives, and this upgrade is seen as a potential catalyst for growth in 2026 and beyond. However, it is too early to speculate on the ASP lift, though the company follows a philosophy of pricing for value. More specifics on ASP will be shared later in the year.
Q:Can you provide updates on the stability of the sales force, any attrition post-leadership changes, and the search for a new leader? Also, how are you viewing the deal pipeline given the guidance of sequentially flat for the first quarter?
A:The sales leadership team is experienced and has maintained focus, as reflected in Q4 results. The company executed at the top of the revised guidance range, with treatments renormalizing and deals closing as expected. The search for a new leader is ongoing, with a leading executive search firm assisting. The pipeline grew across key metrics, including overall size, average deal size, and diversification between new and existing customers, as well as hospital sizes. The company is also making an impact with critical access hospitals in rural areas.
Q:Can you quantify the pipeline growth entering 2025 versus entering 2026? Is there a prioritization for the sales force to reduce the sales cycle?
A:The pipeline growth rate between 2024 and 2025 was similar to the growth rate between 2025 and 2026. Larger deals have longer sales cycles (9-12 months or more), while smaller deals close in 3-6 months. The company focuses on balancing the pipeline to manage sales cycle times effectively. While existing customers may have shorter sales cycles, the company is committed to serving all hospitals and facilities interested in in-sourcing.
Q:Can you provide insights into the guide for 5% to 9% revenue growth, specifically console growth versus consumable growth within that range?
A:The guidance range of 5% to 9% growth reflects a balanced approach across the three primary revenue components. Recurring revenue growth is expected to align with the top-line growth, as seen in consistent growth across console, consumables, and service revenue in 2025.
Q:Is there any update on the timeline to achieve 50% gross margins? Can the current cash balance support reaching profitability, or will additional funds be needed?
A:The company continues to progress towards the 50% gross margin goal, achieving a 500 basis point improvement last year. While no formal timeline is provided, the goal is within the planning horizon. With $173 million in cash and reduced operating cash burn, the company believes it has sufficient funds to reach profitability and beyond.
Q:What is the current state of hospital capital budgets, and how does it impact the backlog for Tablo?
A:There are no material changes observed in hospital capital budgets for 2026. The backlog remains an important lever, and the company feels confident about its position entering 2026.
Q:Is there an upgrade opportunity for the next-gen Tablo for existing customers? What are the new features and capabilities, and how do they enhance clinical utility?
A:Existing customers can upgrade to the next-gen Tablo, while new customers can purchase devices with the new features pre-installed. The upgrades include enhanced cybersecurity, improved device performance, and reliability, which translate to better uptime and user experience. The improvements are based on customer feedback and focus on customer-centric innovation.
Q:How will the next-gen Tablo impact gross margins, and what is included in the guidance?
A:The next-gen Tablo is expected to be a potential tailwind for revenue and gross margins. The company has strategically designed the product to minimize gross margin impact during the transition. The guidance includes the commercial launch in late Q2, with potential revenue and gross margin contributions in the second half of the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the ASP lift for the next-gen Tablo, stating it was too early to speculate and that more specifics would be shared later in the year. Additionally, no formal timeline was given for achieving the 50% gross margin goal, despite acknowledging progress towards it.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act Outset
Cyberattacks
FDA clearance
FDA cybersecurity
Non loss
Non margin
Principal
absorption headwind
benefit Outset
cash use
clearance generation
consumables
cost
customer
cyberattack
cybersecurity requirement
dialysis system
enhancement
evidence
generation Tablo
generation platform
health care
increase
investment technology
mix
outcome
patient care
pattern
provider
safety
satisfaction
stride
system FDA
timing
top
value proposition
week FDA
OM Transcript
Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript
Unknown2-11
While the company has shown improvements in operating expenses and net loss, revenue guidance has been lowered. The Q&A revealed positive sentiment towards the next-gen Tablo's potential impact but lacked specifics on ASP lift and gross margin timelines, which may cause uncertainty. The mixed signals from strong financial metrics but weak guidance, coupled with optimistic future prospects, suggest a neutral short-term stock price movement.
Outset Medical, Inc. (OM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Outset Medical, Inc. (OM) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call presents a mixed picture. Financial performance shows improvement with increased gross margins and reduced losses, but challenges remain with sales leadership changes and guidance reduction. The Q&A reveals uncertainties in deal timing and sales leadership, though no order cancellations occurred. Raised revenue guidance for 2025 is positive, yet the lack of 2026 guidance and management's vague responses add uncertainty. Overall, the sentiment is neutral due to balancing positive financial trends with leadership and guidance concerns.
Outset Medical, Inc. (OM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
OM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
